Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sumitomo Dainippon Pharma and Roivant Sciences Create Broad Strategic Alliance for New Medicines

The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.

Read More »

Zogenix Buys Modis in $400 Million-Plus Deal

Zogenix, with headquarters in Emeryville, California, announced the acquisition of Oakland, California-based Modis. Both companies focus on rare diseases.

Read More »

Mallinckrodt Announces Positive Top-Line Results from Pivotal Phase 3 Study of Terlipressin in Patients with HRS-1

Mallinckrodt plc announced positive top-line results from the company’s pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1).

Read More »

FDA Issues Draft Guidance for Fabry Disease Drugmakers

The U.S. FDA issued a new draft guidance for drugmakers aiming their resources at Fabry disease, a rare genetic disease.

Read More »

U.S. FDA Grants Priority Review for Alnylam’s Givosiran New Drug Application

The U.S. Food and Drug Administration accepted Alnylam Pharmaceuticals Inc.’s New Drug Application for givosiran – an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 in development for the treatment of acute hepatic porphyria – and granted Priority Review for the NDA.

Read More »

FDA Approves Pfizer’s Biosimilar Ruxience for Certain Cancers and Autoimmune Conditions

The U.S. Food and Drug Administration approved Pfizer Inc.’s Ruxience (rituximab-pvvr) – a biosimilar to Rituxan (rituximab) – for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Read More »

Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology

Rare diseases specialist Swedish Orphan Biovitrum (Sobi) agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.

Read More »

Catalyst Pharma sues FDA over approval of cheaper rival drug

Catalyst Pharmaceuticals Inc., under fire for a high price tag on a rare disease drug, sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival medicine.

Read More »

Payer Access Special Feature: The values in value frameworks

Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.

Read More »

The ABCDs of a rare disease launch

The first rule of rare: There are no rules. There are over 7,000 different rare diseases – each with its own symptomology, history, and clinical and political landscape. Most are virgin territory for marketers; only 5 percent have an approved treatment.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom